Edwards Lifesciences (TICKER: EW) Benchmark And Performance Data

there are 11 of samples in the benchmark for Edwards Lifesciences in year 2022 in 2022. The total inventory for Edwards Lifesciences was $802,300,000.00 in 2020. The total inventory for Edwards Lifesciences was $726,700,000.00 in 2021. The total inventory for Edwards Lifesciences was $640,900,000.00 in 2019. The total inventory for Edwards Lifesciences was $607,000,000.00 in 2018. The total inventory for Edwards Lifesciences was $554,900,000.00 in 2017. The total inventory for Edwards Lifesciences was $396,600,000.00 in 2016. The total inventory for Edwards Lifesciences was $339,900,000.00 in 2015. The total inventory for Edwards Lifesciences was $308,900,000.00 in 2013. The total inventory for Edwards Lifesciences was $296,800,000.00 in 2014. The total inventory for Edwards Lifesciences was $281,000,000.00 in 2012. The sales, general, and administrative (SGA) for Edwards Lifesciences was $990,800,000.00 in 2017. The sales, general, and administrative (SGA) for Edwards Lifesciences was $904,700,000.00 in 2016. The sales, general, and administrative (SGA) for Edwards Lifesciences was $858,000,000.00 in 2014. The sales, general, and administrative (SGA) for Edwards Lifesciences was $850,700,000.00 in 2015. The sales, general, and administrative (SGA) for Edwards Lifesciences was $733,400,000.00 in 2013. The sales, general, and administrative (SGA) for Edwards Lifesciences was $697,400,000.00 in 2012. The sales, general, and administrative (SGA) for Edwards Lifesciences was $1,493,700,000.00 in 2021. The sales, general, and administrative (SGA) for Edwards Lifesciences was $1,242,200,000.00 in 2019. The sales, general, and administrative (SGA) for Edwards Lifesciences was $1,228,400,000.00 in 2020. The sales, general, and administrative (SGA) for Edwards Lifesciences was $1,088,500,000.00 in 2018. The sales, general, and administrative (SGA) for Edwards Lifesciences was $$1,568,000,000 in 2022. The revenue volatility for Edwards Lifesciences was 13.32% in 2022. The market capitalization for Edwards Lifesciences was $80,852,155,000.00 in 2014. The market capitalization for Edwards Lifesciences was $73,151,208,000.00 in 2015. The market capitalization for Edwards Lifesciences was $70,665,682,000.00 in 2013. The market capitalization for Edwards Lifesciences was $64,534,467,000.00 in 2012. The market capitalization for Edwards Lifesciences was $58,936,782,000.00 in 2016. The market capitalization for Edwards Lifesciences was $57,343,207,000.00 in 2020. The market capitalization for Edwards Lifesciences was $51,181,022,000.00 in 2017. The market capitalization for Edwards Lifesciences was $50,134,380,000.00 in 2019. The market capitalization for Edwards Lifesciences was $46,128,415,830.00 in 2018. The market capitalization for Edwards Lifesciences was $42,116,441,264.00 in 2021. The market capitalization for Edwards Lifesciences was $$52,214,000,000 in 2022. The gross revenue for Edwards Lifesciences was $5,232,500,000.00 in 2021. The gross revenue for Edwards Lifesciences was $4,386,300,000.00 in 2020. The gross revenue for Edwards Lifesciences was $4,348,000,000.00 in 2019. The gross revenue for Edwards Lifesciences was $3,722,800,000.00 in 2018. The gross revenue for Edwards Lifesciences was $3,435,300,000.00 in 2017. The gross revenue for Edwards Lifesciences was $2,963,700,000.00 in 2016. The gross revenue for Edwards Lifesciences was $2,493,700,000.00 in 2015. The gross revenue for Edwards Lifesciences was $2,322,900,000.00 in 2014. The gross revenue for Edwards Lifesciences was $2,045,500,000.00 in 2013. The gross revenue for Edwards Lifesciences was $1,899,600,000.00 in 2012. The gross revenue for Edwards Lifesciences was $$5,382,000,000 in 2022. The gross margin for Edwards Lifesciences was $33.24% in 2022. The days sales outstanding for Edwards Lifesciences was 42 days in 2022. The days payable outstanding for Edwards Lifesciences was 69 days in 2022. The days of inventory for Edwards Lifesciences was $271 in 2022. The cost of goods sold (COGS) for Edwards Lifesciences was 20.07% in 2022. The cost of goods sold (COGS) for Edwards Lifesciences was $939,400,000.00 in 2018. The cost of goods sold (COGS) for Edwards Lifesciences was $875,300,000.00 in 2017. The cost of goods sold (COGS) for Edwards Lifesciences was $797,400,000.00 in 2016. The cost of goods sold (COGS) for Edwards Lifesciences was $625,600,000.00 in 2014. The cost of goods sold (COGS) for Edwards Lifesciences was $617,200,000.00 in 2015. The cost of goods sold (COGS) for Edwards Lifesciences was $516,600,000.00 in 2013. The cost of goods sold (COGS) for Edwards Lifesciences was $491,000,000.00 in 2012. The cost of goods sold (COGS) for Edwards Lifesciences was $1,248,900,000.00 in 2021. The cost of goods sold (COGS) for Edwards Lifesciences was $1,114,400,000.00 in 2019. The cost of goods sold (COGS) for Edwards Lifesciences was $1,080,600,000.00 in 2020. The cost of goods sold (COGS) for Edwards Lifesciences was $$1,080,000,000 in 2022. The cash to cash cycle time for Edwards Lifesciences was 244 in 2022. The annual percentage growth rate of Edwards Lifesciences was -0.03% in 2022. Edwards Lifesciences in its benchmark peer group, had rank 5 for sales growth in 2022. Edwards Lifesciences in its benchmark peer group, had rank 5 for gross revenue in 2022. Edwards Lifesciences in its benchmark peer group, had rank 10 for cash to cash cycle time in 2022. Edwards Lifesciences in its benchmark peer group, had rank 10 days for days of inventory in 2022. Edwards Lifesciences in its benchmark peer group, had rank 1 for cost of goods sold as a percent of revenue in 2022. Edwards Lifesciences in its benchmark peer group, had rank 1 days for days sales outstanding in 2022. Edwards Lifesciences headquarters region is West. Edwards Lifesciences has ticker symbol EW. Edwards Lifesciences has the following profile: Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.. Edwards Lifesciences has primary indstury Medical Devices. Edwards Lifesciences had a $$1,558,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Edwards Lifesciences had Abbott Laboratories, and QuidelOrtho, and Zimmer Biomet, and Edwards Lifesciences, and Bio-Rad Laboratories, and Boston Scientific, and Align Technology, and Stryker, and AdaptHealth, and Bruker, and DexCom benchmark peer companies for its SIC code in 2022. Edwards Lifesciences had 17,300 number of employees in 2022. Edwards Lifesciences had 112 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Edwards Lifesciences had 106 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Edwards Lifesciences had 1.92% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Edwards Lifesciences had 0.01% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Edwards Lifesciences had 0.00% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Edwards Lifesciences had 0.00% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Edwards Lifesciences had 0 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Edwards Lifesciences can reduce overall cost by $$181,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Edwards Lifesciences can reduce inventory with practices including SKU Reduction in 2022. Edwards Lifesciences can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Edwards Lifesciences can reduce inventory with practices including Forecast Accuracy in 2022. Edwards Lifesciences can reduce inventory with practices including Demand Shaping in 2022. Edwards Lifesciences can reduce days sales outstanding with practices including in 2022. Edwards Lifesciences can increase sales revenue by $$1,558,000,000 improving sales performance to next benchmark tier in 2022. Edwards Lifesciences can increase revenue growth by $$1,000,000 by improving growth performance to next benchmark tier in 2022. Edwards Lifesciences can increase overall revenue by $$1,558,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Edwards Lifesciences can increase days payables outstanding with practices including Strategic Sourcing in 2022. Edwards Lifesciences can increase days payables outstanding by $103,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Edwards Lifesciences can improve total financial performance by $$3,494,000,000 by improving revenue, costs, and working capital in 2022. Edwards Lifesciences can decrease overall working capital by $$1,755,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Edwards Lifesciences can decrease inventory days by $1,652,000,000 days by reducing inventory days to next benchmark tier in 2022. Edwards Lifesciences can decrease days sales outstanding by $0 days by reducing days sales outstanding to next benchmark tier in 2022. Edwards Lifesciences can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Edwards Lifesciences can accelerate revenue growth practices including Pricing Optimization in 2022. Edwards Lifesciences can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 94 days was the measured superior or top ten performance level for days of inventory in Edwards Lifesciences's peer group in 2022. 9.89% was the measured superior or top ten performance level for sales volatility in Edwards Lifesciences's peer group in 2022. 75 days was the measured superior or top ten performance level for cash to cash cycle time in Edwards Lifesciences's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in Edwards Lifesciences's peer group in 2022. 53 days was the measured advantage or top third performance level for days sales outstanding in Edwards Lifesciences's peer group in 2022. 44 days was the measured superior or top ten performance level for days sales outstanding in Edwards Lifesciences's peer group in 2022. 37.24% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Edwards Lifesciences's peer group in 2022. 31.56% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Edwards Lifesciences's peer group in 2022. 30.00% was the measured superior or top ten performance level for gross margin in Edwards Lifesciences's peer group in 2022. 29.10% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Edwards Lifesciences's peer group in 2022. 159 days was the measured parity or middle performance level for days of inventory in Edwards Lifesciences's peer group in 2022. 138 days was the measured parity or middle performance level for cash to cash cycle time in Edwards Lifesciences's peer group in 2022. 13.32% was the measured parity or middle performance level for sales volatility in Edwards Lifesciences's peer group in 2022. 119 days was the measured advantage or top third performance level for cash to cash cycle time in Edwards Lifesciences's peer group in 2022. 11.40% was the measured advantage or top third performance level for sales volatility in Edwards Lifesciences's peer group in 2022. 108 days was the measured advantage or top third performance level for days of inventory in Edwards Lifesciences's peer group in 2022. 0.04% was the measured superior or top ten performance level for sales growth in Edwards Lifesciences's peer group in 2022. -0.05% was the measured parity or middle performance level for sales growth in Edwards Lifesciences's peer group in 2022. -0.02% was the measured advantage or top third performance level for sales growth in Edwards Lifesciences's peer group in 2022. $18.02% was the measured advantage or top third performance level for gross margin in Edwards Lifesciences's peer group in 2022. $17.18% was the measured parity or middle performance level for gross margin in Edwards Lifesciences's peer group in 2022. $$6,940,000,000 was the measured advantage or top third performance level for gross revenue in Edwards Lifesciences's peer group. $$3,735,000,000 was the measured parity or middle performance level for gross revenue in Edwards Lifesciences's peer group in 2022. $$18,449,000,000 was the measured superior or top ten performance level for gross revenue in Edwards Lifesciences's peer group in 2022.